



Clinical trial results:

A Phase 2, Double-Blind, Randomized, Placebo Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)

Summary

EudraCT number	2013-004430-15
Trial protocol	HU PL DK CZ NL
Global end of trial date	14 October 2016

Results information

Result version number	v2 (current)
This version publication date	18 May 2019
First version publication date	29 October 2017
Version creation reason	<ul style="list-style-type: none">• Correction of full data setAdding text to "Limitations and Caveats" section

Trial information

Trial identification

Sponsor protocol code	GS-US-356-0101
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02104583
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Clinical Trials Mailbox, Gilead Sciences , ClinicalTrialDisclosures@gilead.com
Scientific contact	Clinical Trials Mailbox, Gilead Sciences , ClinicalTrialDisclosures@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 October 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 September 2016
Global end of trial reached?	Yes
Global end of trial date	14 October 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) compared to placebo on the overall occurrence of appropriate Implantable Cardioverter-Defibrillator (ICD) interventions (antitachycardia pacing [ATP] or shock) in participants with ICD or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) during the first 24 weeks of treatment.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 September 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 117
Country: Number of subjects enrolled	Israel: 38
Country: Number of subjects enrolled	Canada: 12
Country: Number of subjects enrolled	Netherlands: 12
Country: Number of subjects enrolled	Poland: 57
Country: Number of subjects enrolled	Czech Republic: 8
Country: Number of subjects enrolled	Denmark: 10
Country: Number of subjects enrolled	Germany: 24
Country: Number of subjects enrolled	Hungary: 35
Worldwide total number of subjects	313
EEA total number of subjects	146

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	139
From 65 to 84 years	174
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study sites in North America, Europe and Asia. The first participant was screened on 12 September 2014. The last study visit occurred on 14 October 2016.

Pre-assignment

Screening details:

389 participants were screened.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort 1 Eleclazine 3 mg

Arm description:

Single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months

Arm type	Experimental
Investigational medicinal product name	Eleclazine 3 mg
Investigational medicinal product code	
Other name	GS-6615
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Eleclazine 3 mg orally daily for up to approximately 18 months

Arm title	Cohort 1 Placebo
------------------	------------------

Arm description:

Single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 18 months

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo to match eleclazine for up to approximately 18 months

Arm title	Cohort 2 Eleclazine 3 mg
------------------	--------------------------

Arm description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Participants received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months.

Arm type	Experimental
Investigational medicinal product name	Eleclazine 3 mg
Investigational medicinal product code	
Other name	GS-6615
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Eleclazine 3 mg orally once daily for up to approximately 18 months

Arm title	Cohort 2 Eleclazine 6 mg
------------------	--------------------------

Arm description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Participants received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months

Arm type	Experimental
Investigational medicinal product name	Eleclazine 6 mg
Investigational medicinal product code	
Other name	GS-6615
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Eleclazine 6 mg (2 x 3 mg eleclazine tablets) orally daily for up to approximately 18 months

Arm title	Cohort 2 Placebo
------------------	------------------

Arm description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 18 months.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo to match eleclazine for up to approximately 18 months

Number of subjects in period 1^[1]	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg
Started	48	46	70
Completed	30	35	54
Not completed	18	11	16
Subject required prohibited medication	-	1	1
Withdrew Consent	3	2	-
Adverse Event	3	3	6
Death	2	1	3

Investigator's Discretion	1	-	-
New ICD or CRT-D implanted	2	-	1
Subject required cardiac ablation	6	4	4
Protocol Violation	-	-	1
Lost to follow-up	1	-	-

Number of subjects in period 1 ^[1]	Cohort 2 Eleclazine 6 mg	Cohort 2 Placebo
Started	73	75
Completed	57	63
Not completed	16	12
Subject required prohibited medication	-	1
Withdrew Consent	2	1
Adverse Event	6	1
Death	3	5
Investigator's Discretion	-	-
New ICD or CRT-D implanted	-	-
Subject required cardiac ablation	5	4
Protocol Violation	-	-
Lost to follow-up	-	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: One participant who was enrolled but never treated was not included in the subject disposition table.

Baseline characteristics

Reporting groups

Reporting group title	Cohort 1 Eleclazine 3 mg
-----------------------	--------------------------

Reporting group description:

Single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months

Reporting group title	Cohort 1 Placebo
-----------------------	------------------

Reporting group description:

Single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 18 months

Reporting group title	Cohort 2 Eleclazine 3 mg
-----------------------	--------------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Participants received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months.

Reporting group title	Cohort 2 Eleclazine 6 mg
-----------------------	--------------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Participants received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months

Reporting group title	Cohort 2 Placebo
-----------------------	------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 18 months.

Reporting group values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg
Number of subjects	48	46	70
Age categorical			
Units: Subjects			

Age continuous			
Safety Analysis Set: participants who received at least one dose of study drug			
Units: years			
arithmetic mean	65	64	65
standard deviation	± 10.4	± 9.6	± 10.8
Gender categorical			
Safety Analysis Set			
Units: Subjects			
Female	4	5	8
Male	44	41	62
Race			
Safety Analysis Set			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Black	1	1	0

Native Hawaiian or Pacific Islander	0	0	0
White	47	45	70
Not Permitted	0	0	0
Other	0	0	0
Ethnicity			
Safety Analysis Set			
Units: Subjects			
Hispanic or Latino	1	0	0
Not Hispanic or Latino	47	45	70
Not Permitted	0	1	0
Premature Ventricular Complex (PVC)			
Full Analysis Set: all randomized participants who received at least 1 dose of study drug. 46 participants in cohort 1 eleclazine 3 mg arm, 44 participants in cohort 1 placebo arm, 68 participants in cohort 2 eleclazine 3 mg arm, 73 participants in cohort 2 eleclazine 6 mg arm and 71 participants in cohort 2 placebo arm with available data were analyzed at baseline.			
Units: Count			
arithmetic mean	11002	15560	10646
standard deviation	± 12494.1	± 25009.7	± 16107
Non-Sustained Ventricular Tachycardia (nsVT)			
Full Analysis Set. 46 participants in cohort 1 eleclazine 3 mg arm, 44 participants in cohort 1 placebo arm, 68 participants in cohort 2 eleclazine 3 mg arm, 73 participants in cohort 2 eleclazine 6 mg arm and 71 participants in cohort 2 placebo arm with available data were analyzed at baseline.			
Units: Count			
arithmetic mean	21	49	66
standard deviation	± 59.6	± 191.3	± 369.7
Left Ventricular Ejection Fraction (LVEF)			
Full Analysis Set. 43 participants in cohort 1 eleclazine 3 mg arm, 45 participants in cohort 1 placebo arm, 57 participants in cohort 2 eleclazine 3 mg arm, 60 participants in cohort 2 eleclazine 3 mg arm and 66 participants in cohort 2 placebo arm with available data were analyzed at baseline.			
Units: Percentage			
arithmetic mean	35	38	38
standard deviation	± 12.8	± 12.4	± 12.1

Reporting group values	Cohort 2 Eleclazine 6 mg	Cohort 2 Placebo	Total
Number of subjects	73	75	312
Age categorical			
Units: Subjects			

Age continuous			
Safety Analysis Set: participants who received at least one dose of study drug			
Units: years			
arithmetic mean	65	64	
standard deviation	± 8.3	± 9.4	-
Gender categorical			
Safety Analysis Set			
Units: Subjects			
Female	7	8	32
Male	66	67	280
Race			
Safety Analysis Set			
Units: Subjects			
American Indian or Alaska Native	0	0	0

Asian	0	0	0
Black	2	1	5
Native Hawaiian or Pacific Islander	0	0	0
White	70	71	303
Not Permitted	1	2	3
Other	0	1	1
Ethnicity			
Safety Analysis Set			
Units: Subjects			
Hispanic or Latino	1	0	2
Not Hispanic or Latino	71	73	306
Not Permitted	1	2	4
Premature Ventricular Complex (PVC)			
Full Analysis Set: all randomized participants who received at least 1 dose of study drug. 46 participants in cohort 1 eleclazine 3 mg arm, 44 participants in cohort 1 placebo arm, 68 participants in cohort 2 eleclazine 3 mg arm, 73 participants in cohort 2 eleclazine 6 mg arm and 71 participants in cohort 2 placebo arm with available data were analyzed at baseline.			
Units: Count			
arithmetic mean	8194	6405	
standard deviation	± 10231.4	± 9073	-
Non-Sustained Ventricular Tachycardia (nsVT)			
Full Analysis Set. 46 participants in cohort 1 eleclazine 3 mg arm, 44 participants in cohort 1 placebo arm, 68 participants in cohort 2 eleclazine 3 mg arm, 73 participants in cohort 2 eleclazine 6 mg arm and 71 participants in cohort 2 placebo arm with available data were analyzed at baseline.			
Units: Count			
arithmetic mean	24	5	
standard deviation	± 69.1	± 12.3	-
Left Ventricular Ejection Fraction (LVEF)			
Full Analysis Set. 43 participants in cohort 1 eleclazine 3 mg arm, 45 participants in cohort 1 placebo arm, 57 participants in cohort 2 eleclazine 3 mg arm, 60 participants in cohort 2 eleclazine 3 mg arm and 66 participants in cohort 2 placebo arm with available data were analyzed at baseline.			
Units: Percentage			
arithmetic mean	38	40	
standard deviation	± 13.3	± 13.5	-

End points

End points reporting groups

Reporting group title	Cohort 1 Eleclazine 3 mg
-----------------------	--------------------------

Reporting group description:

Single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months

Reporting group title	Cohort 1 Placebo
-----------------------	------------------

Reporting group description:

Single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 18 months

Reporting group title	Cohort 2 Eleclazine 3 mg
-----------------------	--------------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Participants received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months.

Reporting group title	Cohort 2 Eleclazine 6 mg
-----------------------	--------------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Participants received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months

Reporting group title	Cohort 2 Placebo
-----------------------	------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 18 months.

Subject analysis set title	Cohorts 1 and 2, Eleclazine 3 mg
----------------------------	----------------------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All randomized participants across cohorts 1 and 2 who received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months

Subject analysis set title	Cohorts 1 and 2, Placebo
----------------------------	--------------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All randomized participants across cohorts 1 and 2 who received single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 20 months

Primary: Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24

End point title	Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

The Full Analysis Set (FAS) for ICD/CRT-D (implantable cardioverter-defibrillator device/cardiac resynchronization therapy-defibrillator) event counts (FAS-ICD) was defined as FAS restricted to the subjects who had at least 1 postbaseline ICD/CRT-D interrogation.

Participants in the FAS-ICD analysis set with available data were analyzed.

End point type	Primary
End point timeframe:	
Up to Week 24	

End point values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	46	69	73
Units: Number				
arithmetic mean (standard deviation)	3.3 (± 6.99)	1.9 (± 3.79)	2.6 (± 6.8)	1.1 (± 2.09)

End point values	Cohort 2 Placebo	Cohorts 1 and 2, Eleclazine 3 mg	Cohorts 1 and 2, Placebo	
Subject group type	Reporting group	Subject analysis set	Subject analysis set	
Number of subjects analysed	75	117	121	
Units: Number				
arithmetic mean (standard deviation)	1.5 (± 3.92)	2.8 (± 6.86)	1.7 (± 3.86)	

Statistical analyses

Statistical analysis title	Number of Appropriate ICD Interventions
-----------------------------------	-----------------------------------------

Statistical analysis description:

The primary analysis of overall occurrence of appropriate ICD interventions through Week 24 was performed using a generalized linear model assuming a negative binomial distribution and log link. This model included terms for treatment, implanted device (ICD or CRT-D) and region (US or ROW). Least squares (LS) mean estimates and the corresponding 95% CIs (confidence intervals) were expressed in terms of appropriate ICD intervention average monthly incident rate through Week 24.

Comparison groups	Cohorts 1 and 2, Eleclazine 3 mg v Cohorts 1 and 2, Placebo
Number of subjects included in analysis	238
Analysis specification	Pre-specified
Analysis type	other ^[1]
Parameter estimate	Eleclazine : Placebo Incident Rate Ratio
Point estimate	1.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	2.71

Notes:

[1] - Intergroup comparison

Statistical analysis title	Number of Appropriate ICD Interventions
Statistical analysis description: The primary analysis of overall occurrence of appropriate ICD interventions through Week 24 was performed using a generalized linear model assuming a negative binomial distribution and log link. This model included terms for treatment, implanted device (ICD or CRT-D) and region (US or ROW). LS mean estimates and the corresponding 95% CIs were expressed in terms of appropriate ICD intervention average monthly incident rate through Week 24.	
Comparison groups	Cohort 2 Placebo v Cohort 2 Eleclazine 6 mg
Number of subjects included in analysis	148
Analysis specification	Pre-specified
Analysis type	other ^[2]
Parameter estimate	Eleclazine : Placebo Incident Rate Ratio
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.34
upper limit	1.97

Notes:

[2] - Intergroup Comparison

Secondary: Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through End of Study

End point title	Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through End of Study
End point description: Participants in the FAS-ICD analysis set with available data were analyzed.	
End point type	Secondary
End point timeframe: Up to 20 months	

End point values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	46	69	73
Units: Number				
arithmetic mean (standard deviation)	5.0 (± 7.92)	7.2 (± 20.89)	3.8 (± 8.82)	1.2 (± 2.11)

End point values	Cohort 2 Placebo			
------------------	---------------------	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	75			
Units: Number				
arithmetic mean (standard deviation)	2.0 (\pm 5.55)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Premature Ventricular Complex (PVC) Count as Assessed by Continuous Electrocardiogram [cECG] Monitoring)

End point title	Change From Baseline in Premature Ventricular Complex (PVC) Count as Assessed by Continuous Electrocardiogram [cECG] Monitoring)
-----------------	----------------------------------------------------------------------------------------------------------------------------------

End point description:

Change in PVC from baseline was measured in units of number of episodes/48 hours. Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 12

End point values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	40	58	56
Units: Number				
arithmetic mean (standard deviation)	4282 (\pm 17651.5)	-2347 (\pm 8498.8)	-594 (\pm 13323.0)	-39 (\pm 13575.0)

End point values	Cohort 2 Placebo			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Number				
arithmetic mean (standard deviation)	1541 (\pm 11117.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Nonsustained Ventricular Tachycardia (nsVT)

Count as Assessed by Continuous Electrocardiogram [cECG] Monitoring)

End point title	Change From Baseline in Nonsustained Ventricular Tachycardia (nsVT) Count as Assessed by Continuous Electrocardiogram [cECG] Monitoring)
-----------------	------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Change in nsVT from baseline was measured in units of number of episodes/48 hours. Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 12

End point values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	40	58	56
Units: Number				
arithmetic mean (standard deviation)	44 (± 171.6)	-14 (± 52.2)	-67 (± 400.4)	46 (± 388.4)

End point values	Cohort 2 Placebo			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Number				
arithmetic mean (standard deviation)	2 (± 15.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Occurrence (Total Number) of VT (Ventricular Tachycardia)/VF (Ventricular Fibrillation) (Treated or Untreated) Through Week 24 and End of Study

End point title	Overall Occurrence (Total Number) of VT (Ventricular Tachycardia)/VF (Ventricular Fibrillation) (Treated or Untreated) Through Week 24 and End of Study
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Participants in the Full Analysis Set-ICD with available data were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 24; Up to 20 months

End point values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	46	69	73
Units: Number				
arithmetic mean (standard deviation)				
Total Number of Events Through Week 24	3.56 (± 7.554)	2.07 (± 3.974)	2.74 (± 6.825)	1.44 (± 2.779)
Total Number of Events Through End of Study	5.98 (± 8.907)	7.83 (± 20.949)	4.07 (± 9.088)	1.56 (± 2.794)

End point values	Cohort 2 Placebo			
Subject group type	Reporting group			
Number of subjects analysed	75			
Units: Number				
arithmetic mean (standard deviation)				
Total Number of Events Through Week 24	1.61 (± 3.952)			
Total Number of Events Through End of Study	2.17 (± 5.574)			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Occurrence (Total Number) of Electrical Storms Through Week 24 and End of Study

End point title	Overall Occurrence (Total Number) of Electrical Storms Through Week 24 and End of Study
End point description:	
Full Analysis Set-ICD	
End point type	Secondary
End point timeframe:	
Up to Week 24; Up to 20 Months	

End point values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	46	69	73
Units: Number				
arithmetic mean (standard deviation)				
Total Number of Events Through Week 24	0.15 (± 0.545)	0.15 (± 0.631)	0.23 (± 0.843)	0.03 (± 0.164)
Total Number of Events Through End of Study	0.21 (± 0.582)	0.63 (± 2.037)	0.35 (± 1.041)	0.03 (± 0.164)

End point values	Cohort 2 Placebo			
Subject group type	Reporting group			
Number of subjects analysed	75			
Units: Number				
arithmetic mean (standard deviation)				
Total Number of Events Through Week 24	0.09 (\pm 0.408)			
Total Number of Events Through End of Study	0.12 (\pm 0.614)			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Occurrence (Total Number) of Inappropriate ICD Interventions Through Week 24 and End of Study

End point title	Overall Occurrence (Total Number) of Inappropriate ICD Interventions Through Week 24 and End of Study
End point description:	
Full Analysis Set- ICD	
End point type	Secondary
End point timeframe:	
Up to Week 24; Up to 20 months	

End point values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	46	69	73
Units: Number				
arithmetic mean (standard deviation)				
Total Number of Events Through Week 24	0.17 (\pm 0.753)	0.15 (\pm 0.515)	0.14 (\pm 0.772)	0.12 (\pm 6.22)
Total Number of Events Through End of Study	0.31 (\pm 1.613)	0.41 (\pm 2.072)	0.16 (\pm 0.779)	0.14 (\pm 0.631)

End point values	Cohort 2 Placebo			
Subject group type	Reporting group			
Number of subjects analysed	75			
Units: Number				
arithmetic mean (standard deviation)				

Total Number of Events Through Week 24	0.39 (\pm 2.283)			
Total Number of Events Through End of Study	0.43 (\pm 2.395)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change in Left Ventricular Systolic and Diastolic Function as Assessed by Left Ventricular Ejection Fraction (LVEF)

End point title	Change in Left Ventricular Systolic and Diastolic Function as Assessed by Left Ventricular Ejection Fraction (LVEF)
-----------------	---------------------------------------------------------------------------------------------------------------------

End point description:

Participants in the Full Analysis Set with available data were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 12; Baseline to Week 24

End point values	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	48	46	70	73
Units: Percentage				
arithmetic mean (standard deviation)				
At Week 12(N=41,39,50,46,58 in arms 1,2,3,4,5)	3 (\pm 8.1)	3 (\pm 6.2)	3 (\pm 9.1)	3 (\pm 8.2)
At Week 24(N=35,39,44,43,52 in arms 1,2,3,4,5)	1 (\pm 12.3)	2 (\pm 8.2)	3 (\pm 10.0)	1 (\pm 10.7)

End point values	Cohort 2 Placebo			
Subject group type	Reporting group			
Number of subjects analysed	58			
Units: Percentage				
arithmetic mean (standard deviation)				
At Week 12(N=41,39,50,46,58 in arms 1,2,3,4,5)	1 (\pm 8.2)			
At Week 24(N=35,39,44,43,52 in arms 1,2,3,4,5)	0 (\pm 8.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time From Randomization to the First Occurrence of Appropriate ICD Interventions (ATP or Shock) or Cardiovascular (CV) Death

End point title	Time From Randomization to the First Occurrence of Appropriate ICD Interventions (ATP or Shock) or Cardiovascular (CV) Death
End point description: The median time to the endpoint could only be estimated for the eleclazine 3 mg and placebo groups across cohorts 1 and 2; but first Quartile (Q1) value for cohort 2, eleclazine 6 mg group was 82.0, cohort 2, eleclazine 3 mg was 60.0 and cohort 2, placebo was 56.0. Full Analysis Set.	
End point type	Secondary
End point timeframe: Up to 20 months	

End point values	Cohorts 1 and 2, Eleclazine 3 mg	Cohorts 1 and 2, Placebo		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	118	121		
Units: Days				
median (confidence interval 95%)	243 (147.0 to 281.0)	265 (130.0 to 496.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time From Randomization to the First Occurrence of Cardiovascular (CV) Hospitalization, Emergency Room (ER) visit, or CV Death

End point title	Time From Randomization to the First Occurrence of Cardiovascular (CV) Hospitalization, Emergency Room (ER) visit, or CV Death ^[3]
End point description: The median time to the endpoint could not be estimated for any of the treatment or placebo groups, therefore Q1 values were presented for this endpoint. Full Analysis Set.	
End point type	Secondary
End point timeframe: Up to 20 months	

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Analyses for all participants from the missing baseline cohorts receiving eleclazine 3mg and placebo have been reported as participant analysis sets per treatment group across cohorts 1 and 2.

End point values	Cohort 2 Eleclazine 3 mg	Cohort 2 Eleclazine 6 mg	Cohort 2 Placebo	Cohorts 1 and 2, Eleclazine 3 mg
Subject group type	Reporting group	Reporting group	Reporting group	Subject analysis set
Number of subjects analysed	70	73	75	118
Units: First Quartile (Q1) of the Median Days				

number (not applicable)	125.0	193.0	189.0	144.0
-------------------------	-------	-------	-------	-------

End point values	Cohorts 1 and 2, Placebo			
Subject group type	Subject analysis set			
Number of subjects analysed	121			
Units: First Quartile (Q1) of the Median Days				
number (not applicable)	190.0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 20 months Plus 30 days

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	Cohort 1 Eleclazine 3 mg
-----------------------	--------------------------

Reporting group description:

Single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months

Reporting group title	Cohort 1 Placebo
-----------------------	------------------

Reporting group description:

Single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 18 months

Reporting group title	Cohort 2 Eleclazine 3 mg
-----------------------	--------------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Participants received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months.

Reporting group title	Cohort 2 Eleclazine 6 mg
-----------------------	--------------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Participants received single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 18 months

Reporting group title	Cohort 2 Placebo
-----------------------	------------------

Reporting group description:

Cohort 2 randomization started following the initial safety evaluation in Cohort 1. Single loading dose of placebo to match eleclazine followed by placebo to match eleclazine once daily for up to approximately 18 months.

Serious adverse events	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 48 (56.25%)	25 / 46 (54.35%)	28 / 70 (40.00%)
number of deaths (all causes)	2	2	3
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute leukaemia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Endometrial cancer			

subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung cancer metastatic			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	2 / 48 (4.17%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral vascular disorder			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 48 (2.08%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Phantom shocks			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Cellulitis			
subjects affected / exposed	1 / 48 (2.08%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	3 / 48 (6.25%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 48 (2.08%)	1 / 46 (2.17%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea exertional			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			

subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device dislocation			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device inappropriate shock delivery			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device malfunction			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Anticoagulation drug level below therapeutic			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Chemical burn of skin			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			

subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute right ventricular failure			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anginal equivalent			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 48 (2.08%)	1 / 46 (2.17%)	4 / 70 (5.71%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			

subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	2 / 70 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac failure acute			
subjects affected / exposed	1 / 48 (2.08%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure chronic			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cardiac failure congestive			
subjects affected / exposed	4 / 48 (8.33%)	1 / 46 (2.17%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Chronic left ventricular failure			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cor pulmonale			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	2 / 70 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			

subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia			
subjects affected / exposed	3 / 48 (6.25%)	2 / 46 (4.35%)	5 / 70 (7.14%)
occurrences causally related to treatment / all	1 / 5	0 / 3	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			
subjects affected / exposed	3 / 48 (6.25%)	3 / 46 (6.52%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular flutter			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachyarrhythmia			

subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	11 / 48 (22.92%)	10 / 46 (21.74%)	7 / 70 (10.00%)
occurrences causally related to treatment / all	0 / 14	0 / 15	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain injury			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic encephalopathy			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parosmia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	2 / 48 (4.17%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic anaemia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal detachment			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coeliac artery compression syndrome			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry mouth			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal ulcer			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocholecystis			

subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Petechiae			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 48 (2.08%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Calculus urinary			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gouty arthritis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis pseudomonal			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Septic shock			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Tooth infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 70 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 2 Eleclazine 6 mg	Cohort 2 Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	26 / 73 (35.62%)	26 / 75 (34.67%)	
number of deaths (all causes)	4	5	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute leukaemia			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cancer metastatic			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to central nervous system			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phlebitis			

subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	2 / 73 (2.74%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Phantom shocks			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Cellulitis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 73 (1.37%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			

subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumothorax			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			

Device dislocation			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device inappropriate shock delivery			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device malfunction			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Anticoagulation drug level below therapeutic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Chemical burn of skin			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural complication			

subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute myocardial infarction			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute right ventricular failure			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anginal equivalent			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			

subjects affected / exposed	1 / 73 (1.37%)	4 / 75 (5.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	1 / 73 (1.37%)	2 / 75 (2.67%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Cardiac failure			
subjects affected / exposed	3 / 73 (4.11%)	2 / 75 (2.67%)	
occurrences causally related to treatment / all	0 / 8	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiac failure acute			
subjects affected / exposed	1 / 73 (1.37%)	2 / 75 (2.67%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	2 / 73 (2.74%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiogenic shock			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic left ventricular failure			

subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular dysfunction			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			

subjects affected / exposed	2 / 73 (2.74%)	5 / 75 (6.67%)	
occurrences causally related to treatment / all	1 / 2	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	2 / 73 (2.74%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular flutter			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachyarrhythmia			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	10 / 73 (13.70%)	8 / 75 (10.67%)	
occurrences causally related to treatment / all	0 / 13	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Brain injury			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic encephalopathy			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			

subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parosmia			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic anaemia			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Retinal detachment			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Coeliac artery compression syndrome			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry mouth			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			

subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocholecystis			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Petechiae			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 73 (4.11%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calculus urinary			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Renal impairment			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Clostridium difficile colitis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis pseudomonal			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 73 (1.37%)	3 / 75 (4.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	2 / 73 (2.74%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Tooth infection			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	2 / 73 (2.74%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			

subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort 1 Eleclazine 3 mg	Cohort 1 Placebo	Cohort 2 Eleclazine 3 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 48 (66.67%)	26 / 46 (56.52%)	42 / 70 (60.00%)
Vascular disorders			
Hypotension			
subjects affected / exposed	3 / 48 (6.25%)	2 / 46 (4.35%)	4 / 70 (5.71%)
occurrences (all)	4	2	5
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	3 / 48 (6.25%)	1 / 46 (2.17%)	1 / 70 (1.43%)
occurrences (all)	4	1	1
Chest discomfort			
subjects affected / exposed	4 / 48 (8.33%)	0 / 46 (0.00%)	1 / 70 (1.43%)
occurrences (all)	4	0	1
Chest pain			
subjects affected / exposed	1 / 48 (2.08%)	3 / 46 (6.52%)	3 / 70 (4.29%)
occurrences (all)	1	3	3
Fatigue			
subjects affected / exposed	5 / 48 (10.42%)	7 / 46 (15.22%)	6 / 70 (8.57%)
occurrences (all)	6	7	6
Oedema peripheral			

subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	3 / 46 (6.52%) 3	2 / 70 (2.86%) 2
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	5 / 48 (10.42%) 5	4 / 46 (8.70%) 4	7 / 70 (10.00%) 7
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all) Insomnia subjects affected / exposed occurrences (all)	1 / 48 (2.08%) 1 0 / 48 (0.00%) 0	3 / 46 (6.52%) 3 5 / 46 (10.87%) 5	1 / 70 (1.43%) 1 1 / 70 (1.43%) 1
Investigations Blood magnesium decreased subjects affected / exposed occurrences (all) Hepatic enzyme increased subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3 1 / 48 (2.08%) 1	0 / 46 (0.00%) 0 3 / 46 (6.52%) 3	0 / 70 (0.00%) 0 0 / 70 (0.00%) 0
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)	0 / 48 (0.00%) 0	0 / 46 (0.00%) 0	2 / 70 (2.86%) 2
Cardiac disorders Atrial fibrillation subjects affected / exposed occurrences (all) Ventricular tachycardia subjects affected / exposed occurrences (all)	4 / 48 (8.33%) 4 8 / 48 (16.67%) 23	2 / 46 (4.35%) 2 2 / 46 (4.35%) 2	4 / 70 (5.71%) 4 8 / 70 (11.43%) 10
Nervous system disorders Dizziness subjects affected / exposed occurrences (all) Headache	5 / 48 (10.42%) 5	4 / 46 (8.70%) 4	6 / 70 (8.57%) 7

subjects affected / exposed occurrences (all)	4 / 48 (8.33%) 4	2 / 46 (4.35%) 2	3 / 70 (4.29%) 3
Syncope subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	4 / 46 (8.70%) 4	2 / 70 (2.86%) 2
Gastrointestinal disorders			
Constipation subjects affected / exposed occurrences (all)	4 / 48 (8.33%) 4	1 / 46 (2.17%) 1	2 / 70 (2.86%) 2
Diarrhoea subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	2 / 46 (4.35%) 2	5 / 70 (7.14%) 5
Nausea subjects affected / exposed occurrences (all)	2 / 48 (4.17%) 2	0 / 46 (0.00%) 0	4 / 70 (5.71%) 4
Hepatobiliary disorders			
Cholelithiasis subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	0 / 46 (0.00%) 0	0 / 70 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	0 / 46 (0.00%) 0	1 / 70 (1.43%) 1
Infections and infestations			
Pneumonia subjects affected / exposed occurrences (all)	4 / 48 (8.33%) 5	1 / 46 (2.17%) 1	1 / 70 (1.43%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 3	4 / 46 (8.70%) 6	1 / 70 (1.43%) 2
Metabolism and nutrition disorders			
Hypokalaemia subjects affected / exposed occurrences (all)	3 / 48 (6.25%) 4	2 / 46 (4.35%) 2	2 / 70 (2.86%) 2
Hyponatraemia			

subjects affected / exposed	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 70 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	Cohort 2 Eleclazine 6 mg	Cohort 2 Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	34 / 73 (46.58%)	33 / 75 (44.00%)	
Vascular disorders			
Hypotension			
subjects affected / exposed	2 / 73 (2.74%)	2 / 75 (2.67%)	
occurrences (all)	2	2	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	3 / 73 (4.11%)	1 / 75 (1.33%)	
occurrences (all)	3	1	
Chest discomfort			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
occurrences (all)	0	0	
Chest pain			
subjects affected / exposed	4 / 73 (5.48%)	2 / 75 (2.67%)	
occurrences (all)	4	2	
Fatigue			
subjects affected / exposed	3 / 73 (4.11%)	5 / 75 (6.67%)	
occurrences (all)	4	5	
Oedema peripheral			
subjects affected / exposed	2 / 73 (2.74%)	3 / 75 (4.00%)	
occurrences (all)	2	3	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	2 / 73 (2.74%)	5 / 75 (6.67%)	
occurrences (all)	2	6	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Insomnia			

subjects affected / exposed occurrences (all)	0 / 73 (0.00%) 0	0 / 75 (0.00%) 0	
Investigations			
Blood magnesium decreased subjects affected / exposed occurrences (all)	0 / 73 (0.00%) 0	0 / 75 (0.00%) 0	
Hepatic enzyme increased subjects affected / exposed occurrences (all)	1 / 73 (1.37%) 1	1 / 75 (1.33%) 1	
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	5 / 73 (6.85%) 5	1 / 75 (1.33%) 1	
Cardiac disorders			
Atrial fibrillation subjects affected / exposed occurrences (all)	2 / 73 (2.74%) 2	3 / 75 (4.00%) 3	
Ventricular tachycardia subjects affected / exposed occurrences (all)	7 / 73 (9.59%) 10	9 / 75 (12.00%) 14	
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	8 / 73 (10.96%) 8	2 / 75 (2.67%) 2	
Headache subjects affected / exposed occurrences (all)	3 / 73 (4.11%) 4	3 / 75 (4.00%) 3	
Syncope subjects affected / exposed occurrences (all)	1 / 73 (1.37%) 1	0 / 75 (0.00%) 0	
Gastrointestinal disorders			
Constipation subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4	2 / 75 (2.67%) 2	
Diarrhoea			

subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4	2 / 75 (2.67%) 2	
Nausea subjects affected / exposed occurrences (all)	3 / 73 (4.11%) 3	2 / 75 (2.67%) 2	
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	0 / 73 (0.00%) 0	0 / 75 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	3 / 73 (4.11%) 3	0 / 75 (0.00%) 0	
Infections and infestations Pneumonia subjects affected / exposed occurrences (all)	0 / 73 (0.00%) 0	0 / 75 (0.00%) 0	
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 73 (2.74%) 2	2 / 75 (2.67%) 3	
Metabolism and nutrition disorders Hypokalaemia subjects affected / exposed occurrences (all)	1 / 73 (1.37%) 1	1 / 75 (1.33%) 1	
Hyponatraemia subjects affected / exposed occurrences (all)	4 / 73 (5.48%) 4	0 / 75 (0.00%) 0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

An unplanned review of unblinded clinical trial data was performed in this study that was not prospectively specified in the protocol. There was no impact on the overall integrity or conclusions of the study.

Notes: